Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Jazyk angličtina Země Anglie, Velká Británie Médium electronic
Typ dokumentu časopisecké články, multicentrická studie
PubMed
39187558
PubMed Central
PMC11347671
DOI
10.1038/s41598-024-70182-3
PII: 10.1038/s41598-024-70182-3
Knihovny.cz E-zdroje
- Klíčová slova
- ARON-2 study, Pembrolizumab, Radiation therapy, Real-world data, Stereotactic radiation therapy, Urothelial carcinoma,
- MeSH
- doba přežití bez progrese choroby MeSH
- dospělí MeSH
- humanizované monoklonální protilátky * terapeutické užití aplikace a dávkování MeSH
- karcinom z přechodných buněk terapie patologie mortalita farmakoterapie MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory močového měchýře terapie patologie mortalita farmakoterapie MeSH
- protinádorové látky imunologicky aktivní terapeutické užití MeSH
- radiochirurgie metody MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- urologické nádory patologie mortalita terapie farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Názvy látek
- humanizované monoklonální protilátky * MeSH
- pembrolizumab MeSH Prohlížeč
- protinádorové látky imunologicky aktivní MeSH
The addition of metastasis-directed radiotherapy (MDRT) to immunotherapy in patients with advanced urothelial carcinoma (aUC) has shown promising results. We report the real-world data from the ARON-2 study (NCT05290038) on the impact of conventional (CRT) or stereotactic body radiotherapy (SBRT) on the outcome of aUC patients receiving pembrolizumab after platinum-based-chemotherapy. Medical records of 837 patients were reviewed from 60 institutions in 20 countries. Two hundred and sixty-two patients (31%) received radiotherapy (cohort A), of whom 193 (23%) received CRT and 69 (8%) received SBRT. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. With a median follow-up of 22.7 months, the median OS was 10.2 months, 6.8 months and 16.0 months in no RT, CRT and SBRT subgroups (p = 0.005), with an 1y-OS rates of 47%, 34% and 61%, respectively (p < 0.001). The 1y-OS rate in the SBRT subgroup were significantly higher for both lower (63%) and upper tract UC (68%), for pure urothelial histology (63%) and variant histologies (58%), and for patients with bone (40%) and lymph-node metastases (61%). Median PFS was 4.8 months, 9.6 months and 5.8 months in the CRT, SBRT and no RT subgroups, respectively (p = 0.060). The 1y-PFS rate was significantly higher (48%) in the SBRT population and was confirmed in all patient subsets. The difference in terms of ORR was in favour of SBRT. Our real-world analysis showed that the use of SBRT/pembrolizumab combination may play a role in a subset of aUC patients to increase disease control and possibly overall survival.
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Clinical Oncology Sociedad de Oncología y Hematología del Cesar Valledupar Colombia
Department of Medical Oncology Azienda Ospedaliera Universitaria Maggiore Della Carità Novara Italy
Department of Medical Oncology King Hussein Cancer Center Amman Jordan
Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain
Department of Urology Saitama Medical Center Saitama Medical University Saitama Japan
Department of Urology University Hospital Bonn Bonn Germany
Division of Medical Oncology Markey Cancer Center University of Kentucky Lexington KY 40536 0293 USA
Division of Medical Oncology National Cancer Centre Singapore Singapore Singapore
Genitourinary Medical Oncology Department Fondazione IRCCS Istituto Nazionale Dei Tumori Milan Italy
Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy
Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil
Medical Oncology Department University Hospital La Paz Madrid Spain
Medical Oncology IRCCS Azienda Ospedaliero Universitaria Di Bologna Bologna Italy
Medical Oncology Unit Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy
Medical Oncology Unit Hospital Israelita Albert Einstein São Paulo SP Brazil
Medical Oncology Unit Macerata Hospital Macerata Italy
Medical Oncology Unit Ospedale A Murri Fermo Italy
Oncology and Hematology Department Hospital Sírio Libanês Brasília Federal District Brazil
Oncology Institute of Vojvodina Faculty of Medicine University Novi Sad Novi Sad Serbia
Radiation Oncology Unit Hospital Israelita Albert Einstein São Paulo SP Brazil
Radiation Oncology Unit Macerata Hospital Macerata Italy
Territorial Oncology Operative Complex Unit Casa Della Salute di Aprilia ASL Latina Latina Italy
Zobrazit více v PubMed
Abuodeh, Y., Venkat, P. & Kim, S. Systematic review of case reports on the abscopal effect. PubMed DOI
Herrera, F. G., Bourhis, J. & Coukos, G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. PubMed DOI
Fischer-Valuck, B. W. PubMed DOI PMC
https://clinicaltrials.gov; Accessed on November 28th 2023
Schwartz, L. H. PubMed DOI PMC
Siefker-Radtke, A. O. PubMed DOI
Zubizarreta, E., Van Dyk, J. & Lievens, Y. Analysis of global radiotherapy needs and costs by geographic region and income level. PubMed DOI
